PolyPid’s D-PLEX100: Compelling Phase 3 Results and Strong Commercial Prospects Justify Buy Rating

H.C. Wainwright analyst Brandon Folkes has maintained their bullish stance on PYPD stock, giving a Buy rating today.

Brandon Folkes has given his Buy rating due to a combination of factors surrounding PolyPid’s D-PLEX100. The recent data from the SHIELD II Phase 3 trial demonstrated compelling results, showing a significant reduction in surgical site infections (SSIs) and their severity, which are critical for commercial uptake. The trial data indicated a 38% reduction in the primary endpoint, which includes SSI, all-cause mortality, and re-intervention events, highlighting the potential for approval and commercial success.
Moreover, the consistency of D-PLEX100’s performance across various trials, including a 58% reduction in SSI rates and a 62% reduction in ASEPSIS scores, further validates its effectiveness. These results not only support the approvability of D-PLEX100 but also underline its economic benefits for hospitals by reducing infection rates and severity. The broad potential label and exposure to various surgeries enhance the commercial prospects, justifying the Buy rating and the increased price target.

Folkes covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, PolyPid, and Cormedix. According to TipRanks, Folkes has an average return of -6.6% and a 33.73% success rate on recommended stocks.